ERBB2 and neoplasm: The majority of tumor samples (n = 30; 52.0%) were identified as HER2-enriched (Fig. 3a), followed by basal-like (n = 7; 12.07%), luminal A (n = 6; 10.3%), and luminal B (n = 6; 10.3%).